IL-33, sST2, and CRP in Panic Disorder
Key facts
- Who runs it
- Elazığ Mental Health and Diseases Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 71 people enrolled
- Started
- 7 Jul 2025
- Ended
- 5 Mar 2026
- Type of study
- Observational, 2 groups
- Record updated
- 26 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Other criteria
- For Panic Disorder (PD) Group:; *Inclusion Criteria:; Being between 18-65 years of age; Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder; Not having previously used any medication for psychiatric purposes (drug-naive); Not having any additional active psychiatric disorders besides PD at the current presentation; Absence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer; Not having taken any medication or supplements in the last month; Completing sociodemographic and scale data fully; Volunteering to participate in the study; For PD Group:; *Exclusion Criteria:; Being outside the 18-65 age range; Not meeting the diagnostic criteria for PD according to DSM-5-TR or being in good health; Having a history of psychiatric medication use; Having an additional psychiatric disorder besides PD at the current application; Presence of hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, cancer; Taking any medication or supplement in the last month; Incomplete completion of sociodemographic and scale data; Not volunteering to participate in the study
- For Healthy Control Group:; *Inclusion Criteria:; Being between 18-65 years of age; Not having any active psychiatric disorder; Not having previously used any medication for psychiatric purposes (drug-naive); Not having hypertension, diabetes mellitus, kidney failure, liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer; Not having taken any medication or supplement in the last month; Completing sociodemographic and scale data fully; Volunteering to participate in the study; For Healthy Control Group:; *Exclusion Criteria:; Being outside the 18-65 age range; Having any active psychiatric disorder; Having a history of using psychiatric medication; Having hypertension, diabetes mellitus, renal failure, hepatic failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer; Taking any medication or supplement in the last month; Incomplete completion of sociodemographic and scale data; Not volunteering to participate in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
The 2 groups in the trial
- Panic Disorder (PD)
Adult participants (18-65 years) diagnosed with panic disorder (PD) according to DSM-5-TR criteria. All of the subjects with PD was drug-naive. Subjects were evaluated at baseline. No intervention was assigned by the study protocol. Blood samples were collected for measurement of serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters. Clinical assessments in the PD group included the DSM-5 Panic Disorder Severity Scale (Adult Form). Sociodemographic and clinical data were recorded for all participants.
- Healthy Control (HC)
Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum serum interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels and complete blood count parameters.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study
- Record updated
- 26 October 2026